

*In re: Roberts et al.*

USSN: 09/826,609

Filed: April 5, 2001

Page 3

the application, and in particular, at page 32, lines 5-15. Support for the feature of culturing naïve immune effector cells with the transfected antigen presenting cell is found throughout the application, and in particular, at page 44, lines 18-21. Support for the feature that the educated immune effector cells are screened for their ability to lyse the target cell is found throughout the application, and in particular, at page 44, lines 26-28. Support for the use of a dendritic cell as the antigen presenting cell is found throughout the application, and in particular, at page 11, lines 4-5.

No fee is deemed necessary in connection with the filing of this communication. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 07-1074.

The Examiner is invited to contact the undersigned to discuss any aspects of the Application.

Respectfully submitted,

June 20, 2002  
Date

Elizabeth Lassen

Elizabeth Lassen  
Attorney for Applicants  
Registration No. 37,315  
Telephone: (508) 270-2553  
Facsimile: (508) 872-5415

GENZYME CORPORATION  
15 Pleasant Street Connector  
P.O. Box 9322  
Framingham, Massachusetts 01701-9322